STYLAGE L (2x1ml) - VIVACY
This is a corrective gel for deep and moderate wrinkles. Stylage M is distributed by VIVACY laboratories and is part of a complete range of aesthetic treatments: Stylage S, Stylage L and Stylage XL, which have different concentrations of Hyaluronic Acid
One injection per year is sufficient to restore sagging and fill cracks. It can also be used for lip and nasal reshaping.
♻️ Stylage L is made of biodegradable ingredients
|Composition||Cross-linked hyaluronic acid + Antioxidant|
|Volumes||2 x 1 ml|
|Needles||27 G 1/2|
|Indications||Medium to deep wrinkles|
|Storage||2°C to 25°C|
|Shelf life||12 months|
- 2 pre-filled syringes of 1ml Needles 30G1/2
- Composed of a cross-linked hyaluronic acid concentrated at 24mg/g
- IPN-Like technology which extends its duration of action
- Hyaluronic Acid stimulates the skin's natural hydration over the long term
- Mannitol distributes the gel evenly
- Oligoelements compensate for vitamin deficiencies that cause the dermis to sag
Deep to very deep wrinkles and restoration of volume, cheeks, facial contours and oval and cheekbones by dermal injection into the deep dermis.
STYLAGEBISOFT can also be used in hand rejuvenation techniques by subcutaneous injection into the back of the hand.
Instantly corrects deep and very deep wrinkles
Restores volume to the cheeks, cheekbones and facial contour
Contraindications: 5 days before the injection, stop taking anticoagulants and anti-inflammatory drugs. Not suitable for minors, pregnant or breastfeeding women and people with skin inflammation or an allergic background
Depth of application: Stylage L should be injected into the deep dermis to best treat medium and severe wrinkles
Duration of effectiveness: 9 to 12 months, although some require a touch-up within 30 days
Be careful! This procedure must be performed by a qualified professional
Tolerance and effectiveness
The products in the Stylage® range have proven their biocompatibility in accordance with the international standard ISO 10993.
The optimisation of the gel structure by the IPN-Like® technology generates a product with equivalent remanence for a lower content of cross-linking agent.
In addition, the presence of an antioxidant reduces the intensity of post-injection inflammatory reactions.